Literature DB >> 22832015

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

J E Brazier1, D Rowen, I Mavranezouli, A Tsuchiya, T Young, Y Yang, M Barkham, R Ibbotson.   

Abstract

OBJECTIVES: Generic preference-based measures such as EQ-5D are widely used to estimate quality-adjusted life-years but may not be available or, more importantly, appropriate in some medical conditions. Condition-specific preference-based measures (CSPBMs) provide an alternative to generic measures that may be more relevant in some conditions. This project conducted five studies to examine issues in the development and use of CSPBMS: (1) literature review of measures; (2) deriving health states values for classifications with highly correlated dimensions; (3) impact of condition labelling; (4) impact of add-on dimensions; and (5) comparative performance of measures.
DESIGN: (1) Systematic search and literature review; (2) and (5) psychometric analyses on existing data; (2), (3) and (4) valuation surveys and survey analyses.
SETTING: Valuation surveys conducted using face-to-face interviews in the respondents' homes. PARTICIPANTS: Valuation surveys conducted using representative samples of the UK general population.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: The project developed a CSPBM CORE-6D and analyses AQL-5D, CORE-6D, EORTC-8D, EQ-5D, OAB-5D and SF-6D data.
RESULTS: (1) There was substantial variability in methods used to develop CSPBMs. (2) A new method for generating states using Rasch analysis was undertaken, which successfully dealt with the problem of highly correlated domains. (3) Condition labels affected utility values but this was dependent on the condition and severity of the health state. (4) Adding on an extra dimension affected health-state values and preference weights for other dimensions. (5) The performance of CSPBMs was comparable with that of their parent instrument and of generic preference-based measures with better performance for discrimination between severity groups.
CONCLUSIONS: CSPBMs have an important role for economic evaluation, for which generic measures are inappropriate. However, their use in economic evaluation may be compromised by naming the condition; the exclusion of side effects and comorbidities; and focusing effects. Whether a reduction in comparability should be accepted depends on the extent of any gain in validity and responsiveness. This will depend on the condition and measure in question. Research agenda: (1) The appropriateness of generic preference-based measures should be examined in more conditions (and compared with CSPBMs). (2) Further quantitative and qualitative work is requested into the impact of, and reasons for labelling effects. (3) Use of add-ons for condition-specific measures (for side effects and comorbidities) and as a solution to the limitation of generic measures should be explored. FUNDING: The National Institute for Health Research Health Technology Assessment programme.

Entities:  

Mesh:

Year:  2012        PMID: 22832015     DOI: 10.3310/hta16320

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  57 in total

1.  Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoL™).

Authors:  Andrew Lloyd; Cicely Kerr; Katie Breheny; John Brazier; Aurora Ortiz; Emma Borg
Journal:  Qual Life Res       Date:  2013-09-13       Impact factor: 4.147

Review 2.  How Well Do the Generic Multi-attribute Utility Instruments Incorporate Patient and Public Views Into Their Descriptive Systems?

Authors:  Katherine J Stevens
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

Review 3.  An educational review of the statistical issues in analysing utility data for cost-utility analysis.

Authors:  Rachael Maree Hunter; Gianluca Baio; Thomas Butt; Stephen Morris; Jeff Round; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

4.  Utility Values for the CP-6D, a Cerebral Palsy-Specific Multi-Attribute Utility Instrument, Using a Discrete Choice Experiment.

Authors:  Mina Bahrampour; Richard Norman; Joshua Byrnes; Martin Downes; Paul A Scuffham
Journal:  Patient       Date:  2020-10-19       Impact factor: 3.883

5.  A review of preference-based measures for the assessment of quality of life in children and adolescents with cerebral palsy.

Authors:  Christine Mpundu-Kaambwa; Gang Chen; Elisabeth Huynh; Remo Russo; Julie Ratcliffe
Journal:  Qual Life Res       Date:  2018-03-22       Impact factor: 4.147

Review 6.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 7.  Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.

Authors:  Yiqiao Xin; Emma McIntosh
Journal:  Qual Life Res       Date:  2016-10-24       Impact factor: 4.147

8.  Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.

Authors:  Anne M Rentz; Jonathan W Kowalski; John G Walt; Ron D Hays; John E Brazier; Ren Yu; Paul Lee; Neil Bressler; Dennis A Revicki
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

9.  A systematic review of utility values in children with cerebral palsy.

Authors:  Utsana Tonmukayakul; Long Khanh-Dao Le; Shalika Bohingamu Mudiyanselage; Lidia Engel; Jessica Bucholc; Brendan Mulhern; Rob Carter; Cathrine Mihalopoulos
Journal:  Qual Life Res       Date:  2018-08-02       Impact factor: 4.147

10.  Empirical Validity of a Generic, Preference-Based Capability Wellbeing Instrument (ICECAP-A) in the Context of Spinal Cord Injury.

Authors:  Cassandra Mah; Vanessa K Noonan; Stirling Bryan; David G T Whitehurst
Journal:  Patient       Date:  2021-03       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.